{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorders&page=35",
    "query": {
      "condition": "Growth Disorders",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 1310,
    "total_pages": 131,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorders&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Disorders&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T21:03:45.928Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07541079",
      "title": "A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Giredestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2026-08-25",
      "completion_date": "2034-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 8,
      "location_summary": "Fountain Valley, California • Stockton, California • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Sterling Heights",
          "state": "Michigan"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07541079"
    },
    {
      "nct_id": "NCT00209235",
      "title": "Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pseudohypoparathyroidism Type 1A",
        "Albright Hereditary Osteodystrophy",
        "Pseudopseudohypoparathyroidism"
      ],
      "interventions": [
        {
          "name": "Neurocognitive and psychosocial testing",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Connecticut Children's Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "2 Months to 89 Years"
      },
      "enrollment_count": 600,
      "start_date": "2003-01",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00209235"
    },
    {
      "nct_id": "NCT00966823",
      "title": "Fetal Tracheal Balloon Study in Diaphragmatic Hernia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diaphragmatic Hernia",
        "Lung Disease"
      ],
      "interventions": [
        {
          "name": "Fetal tracheal obstruction with detachable balloon (device)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rhode Island Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2008-09",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00966823"
    },
    {
      "nct_id": "NCT02834780",
      "title": "Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma",
        "Hepatocellular Carcinoma",
        "Liver Cancer",
        "Liver Neoplasms",
        "Hepatic Cancer",
        "Hepatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "H3B-6527",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H3 Biomedicine Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2016-12-28",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834780"
    },
    {
      "nct_id": "NCT00008385",
      "title": "Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "selenium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1772,
      "start_date": "2000-12-18",
      "completion_date": "2019-11",
      "has_results": true,
      "last_update_posted_date": "2023-07-05",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 515,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 339 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00008385"
    },
    {
      "nct_id": "NCT00125580",
      "title": "Healthy Sleeping and Feeding During Infancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Infant sleep instruction",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Penn State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2005-08",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2017-11-24",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 2,
      "location_summary": "Hershey, Pennsylvania • University Park, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "University Park",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125580"
    },
    {
      "nct_id": "NCT06712316",
      "title": "Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pumitamig",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1580,
      "start_date": "2025-01-07",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Concord, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Vail",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06712316"
    },
    {
      "nct_id": "NCT03266198",
      "title": "Fetal 3D Study (Fetal Body Composition and Volumes Study)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fetal Growth Restriction",
        "Fetal Growth Abnormality"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Katherine Grantz",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 2809,
      "start_date": "2016-04-27",
      "completion_date": "2019-09-15",
      "has_results": false,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03266198"
    },
    {
      "nct_id": "NCT06369285",
      "title": "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone Receptor Positive HER-2 Negative Breast Cancer",
        "Metastatic Breast Cancer",
        "Recurrent Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Endocrine therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Puma Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2024-11-19",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06369285"
    },
    {
      "nct_id": "NCT06873035",
      "title": "An Interventional Study of Infigratinib in Children With Hypochondroplasia",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hypochondroplasia"
      ],
      "interventions": [
        {
          "name": "infigratinib 0.128 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "infigratinib 0.25 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-04-22",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-25T21:03:45.928Z",
      "location_count": 8,
      "location_summary": "Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06873035"
    }
  ]
}